We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adtalem (ATGE) Down 3.2% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
A month has gone by since the last earnings report for Adtalem Global Education (ATGE - Free Report) . Shares have lost about 3.2% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Adtalem due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Adtalem's Q2 Earnings Miss, Tepid FY22 View
Adtalem Global Education Inc. reported lackluster second-quarter fiscal 2022 results. The company’s earnings and revenues lagged their respective Zacks Consensus Estimate due to the pandemic-related challenges. Also, ATGE reduced its fiscal 2022 guidance for earnings and revenues due to the pending sale of the Financial Services segment and COVID-related headwinds associated with the Omicron variant.
On a year-over-year basis, revenues and earnings improved on the back of the acquisition of Walden and income tax benefits.
In this connection, Steve Beard, president and CEO of Adtalem, said, “Despite the continued near-term headwinds from the pandemic disproportionally impacting our post licensure nursing programs, we believe our strategic focus, significant scale, and the synergies of the recent Walden acquisition leave us uniquely well positioned to be the leader in helping employers across the healthcare industry meet their critical workforce talent needs. As a result, we are more excited than ever about the opportunities ahead.”
For the fiscal second quarter, the Financial Services segment was treated as discontinued operations.
Earnings & Revenues Discussion
Adjusted earnings of 75 cents per share missed the consensus mark of 96 cents by nearly 22% but increased almost 23% from 61 cents a year ago.
Revenues totaled $371.2 million, lagging the consensus mark of $400 million by 7.2% but increasing 58.4% year over year driven by the Walden acquisition. For the fiscal second quarter, enrollment of new and total students dropped 12.5% and 6.1% year over year, respectively.
Adjusted operating income rose 70% from the prior-year quarter to $70.2 million.
Segment Details
Chamberlain: Revenues in the segment fell 2% from the year-ago figure to $139.1 million. Adjusted operating income also declined 20.6% from the prior-year quarter to $25.8 million, primarily due to increased marketing expense and higher costs associated with a return to in-person campus instruction.
New student enrollment for the November session decreased 0.5% and total student enrollment declined 2.1% from the prior-year level. The downside was primarily owing to COVID-related headwinds in Chamberlain’s post-licensure programs.
Walden: This segment generated revenues of $140.6 million. New and total student enrollment in the quarter decreased 18.3% and 9.1%, respectively, year over year due to COVID-related headwinds in Walden’s post-licensure nursing programs. Adjusted operating income came in at $32.4 million
Medical and Veterinary: Revenues in the segment were down 1% from the year-ago figure to $91.5 million. Total student enrollment declined 6.9% from the prior-year level. During the quarter, the segment did not witness any new enrollment. Nonetheless, adjusted operating income inched up 4.8% from the prior-year quarter to $19.7 million on lower expenses.
Liquidity & Cash Flow
As of Dec 31, 2021, Adtalem had cash and cash equivalents of $275.4 million compared with $476.4 million at fiscal 2021-end. Long-term debt was $1.6 billion, up from $1.07 billion at fiscal 2021-end. For the first six months of fiscal 2022, cash provided by operating activities totaled $1.09 million compared with $63.4 million in the year-ago period.
Fiscal 2022 Guidance Updated
Owing to the pending sale of the Financial Services segment and significant impact of COVID-19 headwinds associated with the Omicron variant, which will have a negative impact on future enrollment, Adtalem reduced its fiscal 2022 guidance.
For fiscal 2022, Adtalem now expects revenues within $1,350-$1,390 million compared with the $1,685-$1,735 million expected earlier. Adjusted earnings per share are now projected within $2.90-$3.10 versus $4.20-$4.45 anticipated earlier. In fiscal 2021, it reported revenues of $1,112.4 million and adjusted earnings of $2.98 per share.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adtalem (ATGE) Down 3.2% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Adtalem Global Education (ATGE - Free Report) . Shares have lost about 3.2% in that time frame, outperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Adtalem due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Adtalem's Q2 Earnings Miss, Tepid FY22 View
Adtalem Global Education Inc. reported lackluster second-quarter fiscal 2022 results. The company’s earnings and revenues lagged their respective Zacks Consensus Estimate due to the pandemic-related challenges. Also, ATGE reduced its fiscal 2022 guidance for earnings and revenues due to the pending sale of the Financial Services segment and COVID-related headwinds associated with the Omicron variant.
On a year-over-year basis, revenues and earnings improved on the back of the acquisition of Walden and income tax benefits.
In this connection, Steve Beard, president and CEO of Adtalem, said, “Despite the continued near-term headwinds from the pandemic disproportionally impacting our post licensure nursing programs, we believe our strategic focus, significant scale, and the synergies of the recent Walden acquisition leave us uniquely well positioned to be the leader in helping employers across the healthcare industry meet their critical workforce talent needs. As a result, we are more excited than ever about the opportunities ahead.”
For the fiscal second quarter, the Financial Services segment was treated as discontinued operations.
Earnings & Revenues Discussion
Adjusted earnings of 75 cents per share missed the consensus mark of 96 cents by nearly 22% but increased almost 23% from 61 cents a year ago.
Revenues totaled $371.2 million, lagging the consensus mark of $400 million by 7.2% but increasing 58.4% year over year driven by the Walden acquisition. For the fiscal second quarter, enrollment of new and total students dropped 12.5% and 6.1% year over year, respectively.
Adjusted operating income rose 70% from the prior-year quarter to $70.2 million.
Segment Details
Chamberlain: Revenues in the segment fell 2% from the year-ago figure to $139.1 million. Adjusted operating income also declined 20.6% from the prior-year quarter to $25.8 million, primarily due to increased marketing expense and higher costs associated with a return to in-person campus instruction.
New student enrollment for the November session decreased 0.5% and total student enrollment declined 2.1% from the prior-year level. The downside was primarily owing to COVID-related headwinds in Chamberlain’s post-licensure programs.
Walden: This segment generated revenues of $140.6 million. New and total student enrollment in the quarter decreased 18.3% and 9.1%, respectively, year over year due to COVID-related headwinds in Walden’s post-licensure nursing programs. Adjusted operating income came in at $32.4 million
Medical and Veterinary: Revenues in the segment were down 1% from the year-ago figure to $91.5 million. Total student enrollment declined 6.9% from the prior-year level. During the quarter, the segment did not witness any new enrollment. Nonetheless, adjusted operating income inched up 4.8% from the prior-year quarter to $19.7 million on lower expenses.
Liquidity & Cash Flow
As of Dec 31, 2021, Adtalem had cash and cash equivalents of $275.4 million compared with $476.4 million at fiscal 2021-end. Long-term debt was $1.6 billion, up from $1.07 billion at fiscal 2021-end. For the first six months of fiscal 2022, cash provided by operating activities totaled $1.09 million compared with $63.4 million in the year-ago period.
Fiscal 2022 Guidance Updated
Owing to the pending sale of the Financial Services segment and significant impact of COVID-19 headwinds associated with the Omicron variant, which will have a negative impact on future enrollment, Adtalem reduced its fiscal 2022 guidance.
For fiscal 2022, Adtalem now expects revenues within $1,350-$1,390 million compared with the $1,685-$1,735 million expected earlier. Adjusted earnings per share are now projected within $2.90-$3.10 versus $4.20-$4.45 anticipated earlier. In fiscal 2021, it reported revenues of $1,112.4 million and adjusted earnings of $2.98 per share.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in fresh estimates.